The reason for this requirement is rather simple: if different types of iTCRI or iTCRII proteins are jointly present in a licensed DC, it will lead to the presentation of multiple antigenic peptides on the surface of a single DC, which will then further lead to the accidental cross-activation of other CD8+ T cells and thus the potential development of autoimmunity. The gene discussed is CD8A; the disease is Autoimmunity.